Topical tirbanibulin resolves recalcitrant condyloma acuminata: Retrospective case series

Abstract

Condyloma acuminata (CA) are anogenital warts caused by human papillomavirus (HPV) infections. Currently, available treatments for CA include cryotherapy, imiquimod, sinecatechins, and podophyllotoxin. These topicals are limited by marked local skin reactions (LSRs), high recurrence rates, or limited accessibility. Clinical response of anogenital warts and HPV-16 (+) vulvar high-grade squamous intraepithelial lesions with topical tirbanibulin has been published recently. Tirbanibulin 1% ointment is a synthetic antiproliferative agent approved by the Food and Drug Administration in 2020 for the treatment of actinic keratoses as a once-daily topical treatment for 5 days. Tirbanibulin exhibits a dual mechanism of action, inhibiting microtubule polymerization by binding tubulin and disrupting Src kinase signaling in actively dividing cells. Here, we report real-world experience with topical tirbanibulin on CA in 5 patients.